Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
מאת: Paul M., Daikos G.L., Durante-Mangoni E., Yahav D., Carmeli Y., Benattar Y.D., Skiada A., Andini R., Eliakim-Raz N., Nutman A., Zusman O., Antoniadou A., Pafundi P.C., Adler A., Dickstein Y., Pavleas I., Zampino R., Daitch V., Bitterman R., Zayyad H., Koppel F., Levi I., Babich T., Friberg L.E., Mouton J.W., Theuretzbacher U., Leibovici L.
פורסם ב: The Lancet Infectious Diseases
תיאור: Background: Colistin–carbapenem combinations are synergistic in vitro against carbapenem-resistant Gram-negative bacteri המשך…